Ironwood Pharmaceuticals Inc Asset Resilience Ratio
Ironwood Pharmaceuticals Inc asset resilience ratio. Ironwood Pharmaceuticals Inc (IRWD) has an Asset Resilience Ratio of 4.76% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Ironwood Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Ironwood Pharmaceuticals Inc (2007–2018)
Asset resilience ratio of Ironwood Pharmaceuticals Inc from 2007 to 2018. This chart shows how Ironwood Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read IRWD total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Ironwood Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Ironwood Pharmaceuticals Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $19.84 Million | 4.76% |
| Total Liquid Assets | $19.84 Million | 4.76% |
Asset Resilience Insights
- Limited Liquidity: Ironwood Pharmaceuticals Inc maintains only 4.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ironwood Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Ironwood Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Ironwood Pharmaceuticals Inc Asset Resilience Ratio by Year (2007–2018)
Ironwood Pharmaceuticals Inc asset resilience ratio by year from 2007 to 2018. The table below shows the annual Asset Resilience Ratio data for Ironwood Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.00% | $0.00 | $332.05 Million | -- |
| 2017-12-31 | 15.80% | $95.68 Million | $605.67 Million | -19.59pp |
| 2016-12-31 | 35.39% | $251.21 Million | $709.82 Million | +6.62pp |
| 2015-12-31 | 28.77% | $178.11 Million | $619.12 Million | -23.42pp |
| 2014-12-31 | 52.18% | $174.04 Million | $333.51 Million | +8.41pp |
| 2013-12-31 | 43.77% | $122.11 Million | $278.96 Million | +30.06pp |
| 2012-12-31 | 13.71% | $31.53 Million | $229.91 Million | -23.01pp |
| 2011-12-31 | 36.72% | $76.73 Million | $208.98 Million | -30.88pp |
| 2010-12-31 | 67.59% | $203.71 Million | $301.37 Million | +51.93pp |
| 2008-12-31 | 15.67% | $22.05 Million | $140.72 Million | -6.05pp |
| 2007-12-31 | 21.71% | $29.51 Million | $135.91 Million | -- |
About Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well … Read more